Small Cell Lung Cancer: A New Era Is Beginning?

Small Cell Lung Cancer: A New Era Is Beginning?

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Muut tekijät: Morabito, Alessandro (Toimittaja), Rolfo, Christian (Toimittaja)
Aineistotyyppi: Kirjan osa
Julkaistu: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Aiheet:
Medicine
immune checkpoint inhibitors
extensive-stage small cell lung cancer
nivolumab
ipilimumab
pembrolizumab
atezolizumab
durvalumab
chemotherapy
small-cell lung cancer
lobectomy
pneumonectomy
radiotherapy
multimodal treatment
immunotherapy
SCLC
PARP
DDR
ICB
synthetic lethality
SLFN11
STING
pathology and classification of SCLC
biology of SCLC
immune-checkpoint inhibitors in SCLC
small cell lung cancer
Immunotherapy
extensive disease
lurbinectedin
gene pathway
pathobiology
targeted therapy
circulating tumor cells
prognostic biomarker
targeted agents
n/a
Linkit:Get Fullteks
DOAB: description of the publication
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

Get Fullteks
DOAB: description of the publication

3rd Floor Main Library

Saatavuus: 3rd Floor Main Library
Hyllypaikka: A1234.567
Nide 1 Saatavissa

Samankaltaisia teoksia